Browse the evidence

Adherence to an ultra low-fat diet (ULF) leads to a compensatory increase in refined grain intake, which may undermine the cardioprotective potential of fat restriction.

If you choose a low-fat diet, be aware that your body may crave carbohydrates. You must actively replace the calories from fat with vegetables and whole foods, not refined grains or sugars. If you find yourself eating more bread or pasta to feel full, your heart health benefits may be negated by the increased refined carbohydrate intake.

Soluble GPNMB (sGPNMB) promotes lipogenesis in white adipose tissue by activating SREBP1c via CD44 binding, thereby acting as a risk factor for obesity progression.

This research highlights that obesity involves complex signaling where soluble proteins released by fat cells can drive further fat storage. While not a direct lifestyle intervention, understanding this mechanism underscores why reducing adiposity (via caloric deficit and exercise) is crucial, as it reduces the source of these pro-lipogenic signals.

Membrane-bound GPNMB on anti-inflammatory macrophages reduces oxidative stress, lipid accumulation, and fibrosis in the liver by interacting with calnexin on Kupffer and stellate cells.

This finding suggests that maintaining healthy macrophage function in fat tissue may have downstream benefits for liver health, potentially reducing the risk of fatty liver disease associated with obesity.

Obesogenic food environments disproportionately increase obesity risk for women compared to men due to biological factors (hormonal modulation of taste/storage), gendered marketing targeting women, and structural burdens (unpaid labor/food security) that limit healthy food access.

Recognize that obesity is not just a personal failure but a result of an environment designed to promote weight gain, which affects women differently due to biological and social factors. Focus on structural changes (policy, food environment) rather than just individual willpower. For women, be aware that marketing and household responsibilities may create unique barriers to healthy eating that require specific, gender-responsive solutions.

Lower-body fat (LBF) is associated with more favorable left ventricular contractility, potentially acting as a metabolic sink that protects against ectopic fat deposition.

While reducing visceral fat is critical, having some lower-body fat may offer metabolic protection by storing excess lipids safely. However, this benefit is overshadowed by high visceral fat.

Semaglutide use is associated with a significantly higher reporting odds ratio for vision impairment and retinopathy compared to other GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, metformin, phentermine, and orlistat.

If you are taking semaglutide, be aware that there is a statistical signal for increased vision impairment reports in post-market data compared to other diabetes or weight loss drugs. This does not mean everyone will experience this, but it warrants vigilance. Ensure you have regular ophthalmological check-ups, especially if you have pre-existing diabetic retinopathy or rapid glycemic changes, and report any visual disturbances to your provider immediately.

Intravenous amino acid infusion improves muscle protein synthesis and reduces perioperative blood loss in total joint arthroplasty patients.

If your surgical team recommends intravenous amino acids during your joint replacement, it may help preserve muscle protein and reduce blood loss. This is a specific medical intervention that complements your surgery, not a substitute for post-operative nutrition.

Brief physician-led weight monitoring and advice during routine primary care consultations does not significantly reduce body weight in moderately obese patients compared to usual care.

For moderately obese patients in primary care, simply having their weight checked and receiving brief advice from their doctor during routine visits is not enough to lose weight. While this method is feasible and doesn't extend visit times, it does not produce significant weight loss compared to standard care. Patients and providers should look for more intensive interventions if weight loss is the goal.

Ghrelin levels, specifically the ratio of unacylated to acylated ghrelin, are altered in NAFLD patients, with decreased plasma unacylated/acylated ghrelin ratio and increased hypothalamic acylated ghrelin expression correlating with insulin resistance and NAFLD severity.

Research indicates that ghrelin signaling is disrupted in NAFLD, with specific changes in ghrelin ratios correlating with insulin resistance. While ghrelin antagonists like pegvisomant are being studied, they are not yet established treatments. Current clinical focus remains on GLP-1 agonists for managing NAFLD.

Bariatric surgery (BS) improves NAFLD outcomes by altering bile acid bioavailability, which activates the Fxr-Glp-1 axis, improves glucose homeostasis, and reestablishes normal ghrelin responses.

For obese patients with NAFLD, bariatric surgery is a viable treatment option that not only reduces weight but also improves liver health through hormonal changes. It reestablishes normal ghrelin responses and activates pathways that improve glucose homeostasis. If you are considering surgery, discuss how it might specifically benefit your liver health beyond weight loss.

GLP-1 receptor agonists protect endothelial function by reducing oxidative stress, inhibiting inflammation, and promoting nitric oxide (NO) production.

This node explains the biological mechanism: GLP-1 drugs help keep blood vessel linings healthy by reducing inflammation and oxidative stress, which prevents the buildup of plaque. This is a key reason why these drugs protect the heart.

GLP-1 receptor agonists reduce foam cell formation and promote anti-inflammatory M2 macrophage polarization, thereby stabilizing atherosclerotic plaques.

GLP-1 drugs help stabilize existing plaque in arteries by changing how immune cells (macrophages) behave. They encourage these cells to become 'anti-inflammatory' (M2 phenotype) and help remove excess cholesterol, which reduces the risk of plaque rupture and heart attack.

DPP-4 inhibitors, specifically sitagliptin, are significantly associated with an increased risk of biliary disorders, including gallbladder-related diseases and biliary malignant tumors.

If you are taking a DPP-4 inhibitor (like sitagliptin), be aware of symptoms like right-sided abdominal pain, nausea, or fever, which could indicate gallbladder issues. Discuss these risks with your doctor, especially if you have been on the medication for a long time.

Specific GLP-1 receptor agonists, semaglutide and liraglutide, are significantly associated with an increased risk of biliary disorders, including gallbladder-related diseases and biliary malignant tumors.

If you are taking Semaglutide or Liraglutide, watch for signs of gallbladder problems, such as pain in the upper right abdomen, nausea, or fever. These drugs can slow down your gallbladder, so report any such symptoms to your doctor promptly.

Sleeve Gastrectomy (SG) in adolescents results in a blunted reduction in Resting Energy Expenditure (REE) relative to total body weight loss compared to lifestyle-induced weight loss, potentially aiding long-term weight maintenance.

For adolescents with severe obesity, Sleeve Gastrectomy appears to preserve metabolic rate better than lifestyle-induced weight loss, which typically causes a sharp drop in energy expenditure. This 'blunting' of metabolic adaptation may help explain why surgery often leads to more sustained weight loss compared to diet and exercise alone.

Genetic variants in GLP1R that increase weight loss efficacy are also associated with an increased risk of nausea and vomiting, suggesting a link between efficacy and side effects.

Research suggests that the same genetic factors that help you lose more weight with GLP-1 medications may also make you more prone to nausea and vomiting. This doesn't mean you must suffer, but it highlights why side effects vary so much between individuals. If you are struggling with severe side effects, it might be worth discussing with your doctor whether a different medication or dose adjustment could help, as your genetics might be driving both your response and your side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily) cause modest bone mineral density (BMD) reduction and increase bone turnover markers (favoring resorption) in people living with obesity, mirroring the effects of calorie restriction.

If you are taking GLP-1 agonists like Wegovy or Saxenda for weight loss, expect a small decrease in bone density (around 2-3%) over a year, similar to losing weight through diet alone. This is not unique to the drug but to the weight loss itself. To protect your bones, prioritize resistance training and ensure you are getting enough calcium and Vitamin D. The benefit of weight loss generally outweighs this modest skeletal risk, but monitoring is advised.

An 8-week combined functional strength and nutrition education program does NOT significantly improve gait speed, health-related quality of life (HRQoL), or protein intake in older adults with pre-frailty and frailty, although exploratory analysis suggests potential trends.

Knowing you need more protein doesn't always mean you will eat more, especially if you live in a facility with limited menu choices. Focus on practical strategies like adding specific high-protein snacks or choosing protein-rich options from existing menus, rather than trying to completely change your diet overnight. Combine this with strength training for the best functional results.

Unintentional weight loss in type 2 diabetes is associated with a higher risk of all-cause mortality, whereas the association with intentional weight loss is unclear.

Unintentional weight loss in type 2 diabetes should be taken seriously as it may signal underlying health issues and is linked to higher mortality. The impact of intentional weight loss on mortality is less clear, so patients should focus on overall health management rather than just weight loss.

General obesity does not significantly increase the risk of incident cardiovascular disease (CVD) events in individuals with type 2 diabetes, although it does increase mortality risk.

For people with diabetes, managing weight is less about preventing heart attacks and more about preventing death from any cause. While obesity doesn't significantly increase CVD risk in diabetics, it does increase mortality risk, so weight management remains important.

Obstetrician-gynecologists generally perceive plant-based dietary patterns as safe and health-promoting for pregnant and lactating patients, yet a significant majority feel inadequately trained to provide nutrition counseling, leading to a discrepancy between positive attitudes and actual clinical recommendations.

For OB/GYNs: Recognize that your positive view of plant-based diets is supported by evidence, but your lack of training is the main barrier to recommending them. Seek out specific nutrition education or refer patients to dietitians to ensure safe implementation during pregnancy.

A healthy vegan diet increases basophil levels in the blood, whereas a healthy omnivorous diet decreases them, indicating diet-specific immune system modulation.

Switching to a healthy vegan diet may alter your immune profile by increasing basophil levels, a type of white blood cell. While this is a specific change, it highlights that plant-based diets actively modulate the immune system rather than just suppressing it.

A healthy vegan diet increases methylation at the ABCG1 locus (potentially elevating Type 2 Diabetes risk) while simultaneously increasing methylation at the PHOSPHO1 locus (potentially reducing Type 2 Diabetes risk), creating a complex and opposing effect on T2D biomarkers.

A healthy vegan diet has complex effects on Type 2 Diabetes biomarkers, increasing methylation at one locus (potentially raising risk) and another (potentially lowering risk). This suggests that the net effect on T2D risk is not straightforward and requires further investigation.

Transitioning from dulaglutide to tirzepatide improves glycemic control (increased time in range, decreased mean glucose) without increasing hypoglycemia in patients with type 2 diabetes undergoing hemodialysis.

For patients with type 2 diabetes on hemodialysis who are not achieving good blood sugar control on dulaglutide, switching to tirzepatide (2.5 mg weekly) can significantly improve blood sugar stability and reduce high blood sugar episodes without increasing the risk of dangerous low blood sugar. This switch should be considered when current therapy fails, keeping in mind that mild stomach issues may occur but are generally manageable.